AC Immunity Shares Jump 18% After Fast-Track Designation on Alzheimer's Treatment
By Jeffrey T. Lewis
AC Immunity's shares rose 18% after the biopharmaceutical company got fast-track designation for a treatment for Alzheimer's Disease from the Food and Drug Administration.
Shares reached $2.33 in pre-market trading and were down 3% from the end of last year through Monday's close.
The company said Tuesday before trading began that its anti-amyloid beta active immunotherapy-candidate, ACI-24.060, got the designation, which is intended to speed up the development and review of drugs that treat serious conditions and fill an unmet medical need.
The goal of the designation is to speed important new drugs through the approval process and get them to patients as quickly as possible, according to the FDA
Write to Jeffrey T. Lewis at jeffrey.lewis@wsj.com
(END) Dow Jones Newswires
June 27, 2023 07:56 ET (11:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
10 Top-Performing Dividend Stocks
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters
-
CVS Earnings: Weak Medicare Advantage Profits Cut Into 2024 Outlook
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry